AGEN
NASDAQ · Biotechnology
Agenus Inc
$7.01
+0.11 (+1.59%)
Financial Highlights (FY 2026)
Revenue
172.66M
Net Income
175.3K
Gross Margin
99.1%
Profit Margin
0.1%
Rev Growth
+5.2%
D/E Ratio
0.41
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 99.1% | 99.1% | 42.9% | 42.9% |
| Operating Margin | 70.5% | 63.5% | -12.1% | -11.8% |
| Profit Margin | 0.1% | 0.1% | -13.6% | -13.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 172.66M | 164.09M | 22.23M | 24.20M |
| Gross Profit | 171.12M | 162.63M | 9.53M | 10.37M |
| Operating Income | 121.79M | 104.18M | -2,685,737 | -2,845,163 |
| Net Income | 175.3K | 150.0K | -3,026,461 | -3,348,387 |
| Gross Margin | 99.1% | 99.1% | 42.9% | 42.9% |
| Operating Margin | 70.5% | 63.5% | -12.1% | -11.8% |
| Profit Margin | 0.1% | 0.1% | -13.6% | -13.8% |
| Rev Growth | +5.2% | +5.2% | +14.5% | +15.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 46.01M | 46.01M | 13.67M | 12.56M |
| Total Equity | 111.56M | 111.56M | 33.53M | 40.20M |
| D/E Ratio | 0.41 | 0.41 | 0.41 | 0.31 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 136.91M | 123.62M | -4,014,681 | -4,691,998 |
| Free Cash Flow | — | — | -2,971,274 | -2,303,520 |